NEWS
Biora Therapeutics to Host Virtual KOL Event on NaviCap™ Targeted Oral Delivery Platform and Results from Phase 1 Clinical Trial of BT-600 on July 17, 2024
Biora Therapeutics is set to host a virtual KOL event on July 17, 2024, to discuss its NaviCap™ Targeted Oral Delivery Platform and present Phase 1 clinical trial results for BT-600. The event will feature experts Bruce Sands and Brian Feagan, who will discuss the current treatment landscape for ulcerative colitis (UC) and the potential benefits of colonic drug delivery. The Phase 1 trial results indicate that BT-600, which uses the NaviCap device to deliver tofacitinib directly to the colon, effectively targets affected tissues in UC patients. The event will include a live Q&A session, and a replay will be available online.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment